Amgen Company Profile (NASDAQ:AMGN)

About Amgen

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AMGN
  • CUSIP: 03116210
Key Metrics:
  • Previous Close: $173.29
  • 50 Day Moving Average: $159.43
  • 200 Day Moving Average: $159.33
  • 52-Week Range: $133.64 - $176.85
  • Trailing P/E Ratio: 16.90
  • Foreward P/E Ratio: 13.49
  • P/E Growth: 2.07
  • Market Cap: $127.48B
  • Outstanding Shares: 736,452,000
  • Beta: 1.15
  • Net Margins: 33.59%
  • Return on Equity: 29.42%
  • Return on Assets: 11.47%
  • Debt-to-Equity Ratio: 1.01%
  • Current Ratio: 4.11%
  • Quick Ratio: 3.86%
Additional Links:
Companies Related to Amgen:

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (?)
Ratings Breakdown: 1 Sell Rating, 9 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.52)
Consensus Price Target: $181.57 (4.87% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetDetails
2/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$175.00View Rating Details
2/13/2017BMO Capital MarketsBoost Price TargetOutperform$202.00 -> $212.00View Rating Details
2/11/2017ArgusSet Price TargetBuy$195.00View Rating Details
2/8/2017MizuhoReiterated RatingBuyView Rating Details
2/5/2017Credit Suisse GroupReiterated RatingHold$178.00View Rating Details
2/3/2017Jefferies Group LLCReiterated RatingBuy$198.00 -> $194.00View Rating Details
2/3/2017CannReiterated RatingBuy$175.00View Rating Details
1/31/2017RBC Capital MarketsSet Price TargetBuy$190.00View Rating Details
2/1/2017Bank of America CorpUpgradeNeutral -> Buy$156.68 -> $192.00View Rating Details
1/10/2017Leerink SwannReiterated RatingMarket PerformView Rating Details
1/8/2017Robert W. BairdReiterated RatingNeutral$157.00 -> $165.00View Rating Details
1/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingPositive$202.00 -> $218.00View Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralView Rating Details
9/28/2016Citigroup Inc.Lower Price TargetNeutral$175.00 -> $172.00View Rating Details
9/28/2016J P Morgan Chase & CoReiterated RatingHoldView Rating Details
9/19/2016Cowen and CompanyReiterated RatingBuyView Rating Details
9/15/2016Piper Jaffray CompaniesSet Price TargetBuy$193.00View Rating Details
8/26/2016Morgan StanleyReiterated RatingOverweight$199.00 -> $198.00View Rating Details
8/26/2016GabelliInitiated CoverageHoldView Rating Details
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00View Rating Details
6/29/2016Sanford C. BernsteinInitiated CoverageMarket Perform$161.00View Rating Details
5/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00View Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00View Rating Details
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00View Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformView Rating Details
8/17/2015Deutsche Bank AGReiterated RatingBuy$195.00View Rating Details
(Data available from 2/21/2015 forward)


Earnings History for Amgen (NASDAQ:AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.10$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
Current Year EPS Consensus Estimate: $12.34 EPS
Next Year EPS Consensus Estimate: $12.83 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$2.48$2.84$2.61
Q2 20163$2.66$2.94$2.77
Q3 20163$2.72$3.01$2.83
Q4 20163$2.63$2.91$2.77
Q1 20173$2.96$3.08$3.03
Q2 20173$2.93$3.17$3.06
Q3 20173$2.99$3.18$3.07
Q4 20173$3.09$3.14$3.12
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Annual Dividend:$4.60
Dividend Yield:2.66%
Dividend Growth:28.60% (3 Year Average)
Payout Ratio:44.92% (Based on Trailing 12 Months of Earnings)
37.28% (Based on Current Year Consensus EPS Estimate)
35.85% (Based on Next Year Consensus EPS Estimate)
Track Record:6 Years of Consecutive Dividend Growth

Dividend History for Amgen (NASDAQ:AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 79.04%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline logoHow Amgen’s Kyprolis Is Positioned in Second-Line Multiple Myeloma Segment (NASDAQ:AMGN) - February 21 at 3:47 PM logoStudy Reveals PCSK9 Drugs Can Save Heart Disease Patients (NASDAQ:AMGN) - February 21 at 3:47 PM logoTop Research Reports for Amgen, Bank of America, and Proctor & Gamble (NASDAQ:AMGN) - February 21 at 3:47 PM
News IconWhat Analysts are Predicting For Amgen Inc. (AMGN), Capital One Financial Corporation (COF)? - The USA Commerce (NASDAQ:AMGN) - February 21 at 7:26 AM
News IconStock Price of Amgen Inc. (AMGN) Increases 3.22% - Energy Index (NASDAQ:AMGN) - February 21 at 7:26 AM logoEnbrel Strengthens Its Position in Rheumatology and Dermatology Segments (NASDAQ:AMGN) - February 20 at 3:27 PM logoAmgen’s Neutropenia Drugs May See Falling Revenues in 2017 (NASDAQ:AMGN) - February 20 at 3:27 PM logoRoche Sues Amgen Over Avastin Biosimilar Drug (NASDAQ:AMGN) - February 20 at 3:27 PM logoWhat Makes Amgen A Compelling Buy In 2017? - Seeking Alpha (NASDAQ:AMGN) - February 19 at 7:22 AM logoAMGEN INC Financials (NASDAQ:AMGN) - February 18 at 3:28 PM logoAMGEN INC Financials (NASDAQ:AMGN) - February 18 at 3:28 PM
News IconAmgen, Inc (NASDAQ:AMGN) Has Submitted A Supplemental Biologics Licence Application For Their Treatment Drug BLINCYTO (NASDAQ:AMGN) - February 16 at 8:36 PM logoAmgen Applies for Leukemia Drug Label Expansion (NASDAQ:AMGN) - February 16 at 8:36 PM logoAmgen Estimates Modest Revenue Performance in 2017 (NASDAQ:AMGN) - February 16 at 8:36 PM logoDon't Count on Valeant's New Drug to Save the Day (NASDAQ:AMGN) - February 16 at 8:36 PM logoAmgen Commits to Reaching Its Long-Term Financial Targets in 2018 (NASDAQ:AMGN) - February 16 at 8:36 PM
News IconAnalyst's Proposition on Amgen Inc. (AMGN), Exelon Corporation (EXC) - The USA Commerce (NASDAQ:AMGN) - February 16 at 3:35 PM logoShould You Buy Amgen, Inc. (AMGN) Stock? 3 Pros, 3 Cons - (NASDAQ:AMGN) - February 16 at 3:35 PM logoHealth Care ETF Has Been Ailing (NASDAQ:AMGN) - February 16 at 3:35 PM logoGenentech fighting to delay looming market entry of Amgen's Avastin biosimilar (NASDAQ:AMGN) - February 16 at 2:04 PM logoShould You Buy Amgen, Inc. (AMGN) Stock? 3 Pros, 3 Cons (NASDAQ:AMGN) - February 16 at 1:09 PM logoWhy Amgen's Becoming One of My Top Dividend Stocks to Buy (NASDAQ:AMGN) - February 16 at 9:21 AM
News IconAnalyst's Predictions on KKR & Co. LP (KKR), Amgen Inc. (AMGN) - StockNewsJournal (NASDAQ:AMGN) - February 16 at 8:26 AM
News IconImpact of Brokerage Rating on Amgen Inc.(AMGN) - Highland Mirror (NASDAQ:AMGN) - February 16 at 8:26 AM logoAmgen Seeks Leukemia Drug Label Expansion (AMGN) - Investopedia (NASDAQ:AMGN) - February 16 at 8:25 AM logoProof the rally is real (NASDAQ:AMGN) - February 16 at 8:25 AM logoCramer fires back at naysayers: Here's your proof that th... (NASDAQ:AMGN) - February 16 at 8:25 AM logoAmgen Submits SBLA For Blincyto - Quick Facts (NASDAQ:AMGN) - February 14 at 9:09 PM logoAmgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (NASDAQ:AMGN) - February 14 at 9:09 PM logo9:01 am Amgen submits supplemental Biologics License Application to the FDA for BLINCYTO (blinatumomab) to include overall survival data from the Phase 3 TOWER study (NASDAQ:AMGN) - February 14 at 9:09 PM logoAMGEN INC Files SEC form 10-K, Annual Report (NASDAQ:AMGN) - February 14 at 9:09 PM
News IconAnalyst's Indicator Review for Hess Corporation (HES), Amgen Inc. (AMGN) - The USA Commerce (NASDAQ:AMGN) - February 14 at 4:08 PM
News IconHow Does Amgen Inc. (AMGN) Stack Up Right Now? - StockNewsJournal (NASDAQ:AMGN) - February 14 at 4:08 PM
News Icon6500 AMGN Apr21 115 puts went up in 1 block on the PHLX. (NASDAQ:AMGN) - February 13 at 8:59 PM
News IconABR Of Amgen Inc. (NASDAQ:AMGN) Stock At 2.16 - Stock Observer (NASDAQ:AMGN) - February 13 at 3:58 PM
News IconIs It Time to go for CBS Corporation (CBS), Amgen Inc. (AMGN)? - StockNewsJournal (NASDAQ:AMGN) - February 13 at 3:58 PM
News IconAcorda Therapeutics, Inc. (ACOR), Amgen Inc. (AMGN) (NASDAQ:AMGN) - February 10 at 8:59 PM
News IconAverage Brokerage Rating Of Marathon Petroleum Corporation (MPC), Amgen Inc. (AMGN) - The USA Commerce (NASDAQ:AMGN) - February 10 at 3:59 PM logoBetter Buy: Amgen Inc. vs. Celgene - Motley Fool (NASDAQ:AMGN) - February 10 at 3:59 PM logoAmgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 13, 2017 - Nasdaq (NASDAQ:AMGN) - February 10 at 3:59 PM logoMajor Biotechs Scare Off Loads of Short Sellers (NASDAQ:AMGN) - February 10 at 3:59 PM
News IconLeading stocks in today’s market: Amgen Inc. (NASDAQ:AMGN) (NASDAQ:AMGN) - February 10 at 1:35 AM logoA Heart-Stopping Patent Injunction Stay For Sanofi (NASDAQ:AMGN) - February 10 at 1:35 AM logoRegeneron forecasts 2017 U.S. Eylea sales growth below estimates (NASDAQ:AMGN) - February 10 at 1:35 AM
News IconThe Technical Case for and Against Amgen Inc. (AMGN) - The USA Commerce (NASDAQ:AMGN) - February 9 at 8:34 PM
News IconWhy Investors remained confident on Tyson Foods, Inc. (TSN), Amgen Inc. (AMGN)? - StockNewsJournal (NASDAQ:AMGN) - February 9 at 3:31 PM logoAmgen Rival Allowed to Keep Drug on Market (AMGN, REGN) - Investopedia (NASDAQ:AMGN) - February 9 at 3:31 PM logoRegeneron: Whiplash! (NASDAQ:AMGN) - February 9 at 3:31 PM logoRegeneron Defies Light Q4 Sales, Eylea Outlook On Amgen-Rivaling LDL Win (NASDAQ:AMGN) - February 9 at 3:31 PM logoFDA Approves Amgen, Inc. (NASDAQ:AMGN) Drug For Treating Secondary Hyperparathyroidism (NASDAQ:AMGN) - February 9 at 1:45 AM


What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Tuesday, December 20th. Shareholders of record on Wednesday, February 15th will be given a dividend of $1.15 per share on Wednesday, March 8th. This represents a $4.60 annualized dividend and a yield of 2.66%. The ex-dividend date of this dividend is Monday, February 13th. This is a positive change from Amgen's previous quarterly dividend of $1.00.

Where is Amgen's stock going? Where will Amgen's stock price be in 2017?

23 analysts have issued twelve-month price targets for Amgen's stock. Their forecasts range from $135.00 to $218.00. On average, they expect Amgen's stock price to reach $181.57 in the next twelve months.

When will Amgen announce their earnings?

Amgen is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • BMO Capital Markets analysts commented, "Addition of CV outcomes data to the Repatha label and launch of erenumab for migraine (both in 2018) could enable Amgen to grow revenues in the face of a declining legacy business. This combined with margin expansion supports upward revision to our earnings estimates and a higher price target of $202 (vs. $197). We expect presentation of the FOURIER outcomes data at the ACC conference on March 17 to meet payor criteria for a 20% improvement in MACE and support opening of access, driving our $5B peak sales estimate." (2/3/2017)
  • Cann analysts commented, "We now estimate Amgen's revenue will grow at a compound annual rate of 2.5% for the next four years, with diluted GAAP EPS growth of 8.5% per year. Based on our increased earnings estimates, we are raising our target price to $175 from our previous target price of $166." (2/3/2017)
  • According to Zacks Investment Research, "Amgen growth products – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are performing well. Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. Amgen has a positive record of earnings surprises in recent quarters. Amgen’s shares surpassed that of Biomed-Genetics industry in 2016. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. Biosimilars are starting to have a negative impact on key products like Neupogen and Neulasta in the EU. Moreover, minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017. Estimates have also declined lately ahead of the company’s Q4 earnings release." (1/3/2017)

  • Jefferies Group LLC analysts commented, "Impella secured approval in Japan; the late summer approval was largely on target. The label is somewhat different than in the US: Impella is indicated for drug-resistant acute heart failure, but not prophylactic or elective use." (9/28/2016)

  • Credit Suisse Group analysts commented, "We remain focused on the two AMG 334 episodic migraine Ph3 readouts, ABP- 501 potential approval, full Ph3 FRAME results of Romosozumab and Kyprolis Clarion data in the 2H 2016." (7/28/2016)

Who owns Amgen stock?

Amgen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (5.48%), State Street Corp (4.61%), Franklin Resources Inc. (1.12%), Janus Capital Management LLC (0.94%), Loomis Sayles & Co. L P (0.41%) and Orbimed Advisors LLC (0.32%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Fred Hassan, Madhavan Balachandran, Sean E Harper and Stuart A Tross.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Thrivent Financial for Lutherans, Renaissance Technologies LLC, Orbimed Advisors LLC, Artemis Investment Management LLP, AMF Pensionsforsakring AB, Credit Agricole S A and Fiera Capital Corp. Company insiders that have sold Amgen stock in the last year include Annette Louise Such, David Baltimore, Madhavan Balachandran and Sean E Harper.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Asset Management One Co. Ltd., State Street Corp, Russell Investments Group Ltd., FIL Ltd, Prudential PLC and ING Groep NV.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Amgen stock cost?

One share of Amgen stock can currently be purchased for approximately $173.14.

Amgen (NASDAQ:AMGN) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Earnings History Chart

Earnings by Quarter for Amgen (NASDAQ:AMGN)

Dividend History Chart

Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Last Updated on 2/21/2017 by Staff